💨 Abstract

The U.S. approved a new COVID-19 vaccine by Moderna, called mNexspike, as an additional option for high-risk groups. It's designed to be a lower dose and is approved for adults 65 and older and people aged 12 to 64 with health conditions. The FDA's approval was based on a study showing it's safe and at least as effective as Moderna's existing vaccine, Spikevax.

Courtesy: WTOP Staff